What is the recommended mesalazine (5‑ASA) dosage for ulcerative colitis based on disease extent (proctitis, left‑sided colitis, extensive or pancolitis)?

Mesalazine Dosing for Ulcerative Colitis

For mild-to-moderate ulcerative colitis, use mesalazine at >2 g/day (optimally 2.4-4.8 g/day oral) with dosing tailored to disease extent: standard-dose (2-3 g/day) for extensive disease, high-dose (>3 g/day) for moderate disease or suboptimal response, and topical mesalazine (suppositories for proctitis, enemas for proctosigmoiditis) as preferred first-line for distal disease. 1, 2

Disease Extent-Based Dosing Algorithm

Extensive or Pancolitis (Disease Beyond Splenic Flexure)

• Initial therapy: Oral mesalazine 2-3 g/day (standard dose) 2
• Once-daily dosing is as effective as divided doses and improves adherence 1, 2
• Consider adding rectal mesalazine to oral therapy for enhanced efficacy 2
• Escalate to high-dose (>3 g/day, up to 4.8 g/day) if suboptimal response to standard dose or moderate disease activity 2

The 2025 British Society of Gastroenterology guidelines emphasize that more severe disease should be treated with maximum higher doses until remission is induced 1. The dose-response relationship is well-established, with 4.8 g/day showing superior efficacy compared to 2.4 g/day in moderately active disease 3, 4.

Left-Sided Colitis (Disease to Splenic Flexure)

• Combination therapy is optimal: Oral mesalazine 2-3 g/day PLUS rectal mesalazine 2
• Combined oral and topical therapy ranks first for efficacy in left-sided disease 3
• If using oral therapy alone, consider high-dose (>3 g/day) 2
• Rectal mesalazine enemas (4 g) once daily, retained overnight 5

Proctosigmoiditis (Disease to Sigmoid)

• First-line: Mesalazine enemas (4 g once daily) are superior to oral therapy 2
• Alternative: Oral mesalazine if patient strongly prefers convenience over maximal efficacy 2
• If inadequate response to rectal mesalazine, add oral therapy or switch to rectal corticosteroids 2

Proctitis (Disease Limited to Rectum)

• First-line: Mesalazine suppositories (strong recommendation) 2
• Topical therapy is significantly more effective than oral for distal disease 3
• Oral mesalazine is acceptable if patient prioritizes convenience 2

Maintenance Dosing

The lowest effective maintenance dose should be used 1:

• Standard maintenance: 1.6-2.4 g/day for most patients 6, 7
• Higher maintenance (3.2-4.8 g/day) may be needed for patients who required high-dose induction or have history of frequent relapses 7
• Continue topical therapy (twice weekly) in high-risk patients with distal disease 6

A post hoc analysis demonstrated that patients achieving remission with 3.2 g/day could maintain with 1.6 g/day (65.8% remission at 38 weeks), while partial responders benefited from continuing 3.2 g/day or escalating to 4.8 g/day 7.

Key Implementation Points

Dosing Schedule

• Once-daily dosing is equally effective as divided doses for both induction and maintenance 1, 2
• Improves adherence without compromising efficacy
• Rectal therapy: administer at bedtime, retain 8 hours 5

Common Pitfalls to Avoid

1. Underdosing: Using <2 g/day is inadequate; the dose-response relationship clearly favors higher doses 1, 3, 4
2. Not using topical therapy for distal disease: Topical mesalazine ranks highest for proctitis/proctosigmoiditis and should be first-line 3, 2
3. Premature escalation: Extend treatment duration at adequate doses (up to 38 weeks) before declaring failure 7
4. Ignoring combination therapy: For left-sided disease, combined oral + rectal therapy is more effective than either alone 3, 2

Safety Considerations

• Evaluate renal function before initiating and periodically during treatment 5
• Ensure adequate hydration to prevent nephrolithiasis 5
• Mesalazine is generally well-tolerated with rare serious adverse effects 1, 8
• Contains sulfites (potassium metabisulfite); contraindicated in sulfite hypersensitivity 5

Treatment Duration

• Induction: 3-6 weeks for rectal therapy 5; 8-12 weeks for oral therapy 7
• Patients with suboptimal response at 8 weeks may benefit from extended treatment (up to 38 weeks) at the same or higher dose before escalating to corticosteroids 7

When to Escalate Beyond Mesalazine

If inadequate response to optimized mesalazine (high-dose oral + rectal therapy for adequate duration), escalate to oral corticosteroids (prednisone or budesonide MMX) 2. The 2025 BSG guidelines note this is appropriate for moderate-to-severe disease requiring more aggressive initial therapy 1.